CCMG
NBIX icon

Connecticut Capital Management Group’s Neurocrine Biosciences NBIX Stock Holding History

Connecticut Capital Management Group’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$241K Buy
+1,432
New +$212K 0.19% 108
2026
Q1 		– Sell
-1,505
Closed -$213K – 118
2025
Q4 		$213K Buy
+1,505
New +$218K 0.2% 97

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Connecticut Capital Management Group's NBIX Position: Q2 2026 in Review

Connecticut Capital Management Group opened a new position in Neurocrine Biosciences (NBIX) in Q2 2026: 1,432 shares worth $241K. The stake represents 0.19% of the portfolio and ranks #108 among its holdings. This is a return to the name: Connecticut Capital Management Group previously reported a position in NBIX as recently as Q4 2025.

Connecticut Capital Management Group first reported a position in NBIX in Q4 2025 and has held it in 2 quarters since. 770 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Connecticut Capital Management Group held 1,432 shares of Neurocrine Biosciences worth $241K as of Q2 2026.
  • Neurocrine Biosciences was a new Connecticut Capital Management Group position in Q2 2026.
  • Neurocrine Biosciences made up 0.19% of Connecticut Capital Management Group's portfolio in Q2 2026, its #108 holding.
  • Connecticut Capital Management Group first reported a position in Neurocrine Biosciences in Q4 2025 and has held it in 2 quarters since.
  • 770 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Connecticut Capital Management Group's 13F filing for Q2 2026, filed 20 Jul 2026.